Humacyte Stock
Regenerative Medical Technology Company
Sign up today and learn more about Humacyte Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Humacyte Stock
Humacyte, Inc. develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products called human acellular vessels (HAV) for regenerative medicine and vascular surgery applications. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.
Investors
Funding History
| January 2015 | $74.1M |
|---|---|
| October 2015 | $136M |
| March 2018 | $75.0M |
| June 2018 | $150M |
Management
Chief Executive Officer
Jeffrey Lawson
Chief Financial Officer
Douglas Blankenship
Press
Business Wire - Mar, 27 2020
Science Translational Medicine Publishes Results That Humacyte’s “Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels following Human Implantation”Business Wire - Mar, 2 2020
Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of EngineeringBusiness Wire - Apr, 8 2019
Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortiumxconomy - Mar, 8 2019
Humacyte Appoints Chris Fang Chief Medical Officerxconomy - Jun, 25 2018
Humacyte Promotes Jeffrey Lawson to Chief Executiveprnewswire - Jun, 11 2018
Fresenius Medical Care and Humacyte announce strategic global partnership supported by a $150M equity investmentbusinesswire - Mar, 9 2018
Humacyte Closes $75 Million Series C FinancingEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
